A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies

This is an early-phase study testing a new investigational drug called CG009301 in people with blood cancers — specifically acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or acute lymphoblastic leukemia (ALL) — that has come back or stopped responding to standard treatments. **You may be eligible if...** - You are 18–74 years old - You have a confirmed diagnosis of relapsed or refractory AML, MDS, or ALL, and no standard treatment options remain - Your general health (ECOG score) is 0 or 1 - Your expected survival is at least 3 months - Your organs are functioning at acceptable levels **You may NOT be eligible if...** - You have leukemia in the brain with neurological or psychiatric symptoms - You have had chemotherapy, immunotherapy, or targeted therapy in the past 4 weeks (or 5 half-lives) - You have a serious uncontrolled infection, heart condition, or other severe medical illness - You have active autoimmune disease - You have HIV, active hepatitis B, or hepatitis C - You have had an allogeneic stem cell transplant in the past 12 months Talk to your doctor to see if this trial is right for you.